John Glenn Sells 2,500 Shares of Iradimed Corporation (NASDAQ:IRMD) Stock

Iradimed Corporation (NASDAQ:IRMD) CFO John Glenn sold 2,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the transaction, the chief financial officer now owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This trade represents a 36.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Iradimed Trading Down 0.4 %

IRMD stock opened at $53.64 on Wednesday. The business’s 50-day moving average is $51.79 and its 200 day moving average is $47.35. Iradimed Corporation has a 12-month low of $40.18 and a 12-month high of $57.95. The stock has a market cap of $679.62 million, a price-to-earnings ratio of 36.74 and a beta of 0.82.

Iradimed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date was Friday, November 15th. Iradimed’s payout ratio is 41.10%.

Institutional Trading of Iradimed

Several large investors have recently bought and sold shares of the business. Liontrust Investment Partners LLP acquired a new stake in shares of Iradimed in the second quarter valued at approximately $2,830,000. Charles Schwab Investment Management Inc. increased its stake in shares of Iradimed by 189.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider’s stock worth $3,351,000 after acquiring an additional 43,635 shares during the last quarter. Oak Ridge Investments LLC purchased a new position in shares of Iradimed during the 3rd quarter worth $2,188,000. Eagle Asset Management Inc. acquired a new position in shares of Iradimed during the 3rd quarter valued at about $1,239,000. Finally, Kings Path Partners LLC purchased a new position in Iradimed during the second quarter worth about $1,055,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.